Efficacy of topical diphenylcyclopropenone maintenance treatment for patients with alopecia areata: A retrospective study To the Editor: Diphenylcyclopropenone (DPCP) immunotherapy is widely used in the treatment of alopecia areata (AA). 1 Few studies have described the efficacy of DPCP maintenance treatment (DPCP-MT), and the relapse rate (RR) varies.
2-4 Therefore, we sought to clarify whether DPCP-MT prevents recurrence and to identify associated variables.
Among 230 AA patients treated with DPCP, 63 patients who achieved and maintained a complete response (defined as [90% regrowth) for at least 6 weeks were included (Fig 1) . Forty-one patients who received continuous regular treatments afterwards were classified as the maintenance-treated group. DPCP was applied to the entire scalp, including nonlesional skin and previous AA lesions that had already improved. Twenty-two patients who did not receive further DPCP treatment, including subjects lost to follow-up, were classified as the maintenanceuntreated group. A telephone questionnaire was conducted with 8 patients for whom relapse information was not available because they were lost to follow-up. Relapse was defined as recurrence of $25% hair loss. Interval initial was defined as the number of weeks from the start of treatment with DPCP to the transition to DPCP-MT, and Interval mnt was defined as the number of weeks on DPCP-MT. The RR was 24.4% in the maintenance-treated group and 68.2% in the maintenance-untreated group. There was no difference in adverse effects between groups. On Kaplan-Meier analysis, the maintenance-untreated group relapsed earlier than the maintenance-treated group (hazard ratio 4.869; 95% confidence interval 3.370-21.380, P \.001). On Cox regression analysis, 3 features of AA were observed to be prognostic factors on univariate analysis and were further evaluated with multivariate analysis. The maximum extent of scalp hair loss, a well-known prognostic factor, correlated significantly with relapse (P ¼ .034). Moreover, receiving DPCP-MT correlated with a low RR in patients with AA (P \ .001) and was confirmed to be another independent prognostic factor (Supplemental Table  I ; available at http://www.jaad.org). These results might have been due to our treatment protocol. Because DPCP was applied to both lesional and nonlesional scalp, subclinical lesions related to AA also might have been normalized by the DPCP-MT, via regulating the immune response, before clinical symptoms became apparent.
For the maintenance-treated group, the Interval mnt was longer for relapsed patients than for nonrelapsed patients. Because the Interval mnt gradually increased after switching to DPCP-MT, we evaluated factors related to the treatment interval. The ratio of treatment interval before and after transition to DPCP-MT was greater, and the period before the first increase in Interval mnt after transition to DPCP-MT was shorter in relapsed patients (Fig 2) . These findings suggest that changes in treatment intervals might affect the outcomes of DPCP-MT. Gulati et al 5 reported that the regulated immune response lasted for 14 days when 0.04% DPCP was applied to normal skin. Although there are differences between normal skin and alopecia lesions, the intended immune response might not be maintained at longer treatment intervals.
Limitations of this study included its small sample size and retrospective design. However, this study suggests that DPCP-MT can be used to maintain AA Patients with moderate-to-severe AA were treated with DPCP contact immunotherapy. DPCP treatment concentration was determined according to treatment response and clinical course, and all patients were treated with 0.01% to 0.1% DPCP. After sensitization, patients visited the hospital once a week, and the treatment interval was adjusted to once every 2 weeks or once every 3 weeks, depending on treatment response and compliance. Clinical improvement was defined as a [90% improvement of hair loss. If these improvements lasted [6 weeks, subsequent treatment was defined as DPCP-MT. After switching to DPCP-MT, the patient continued treatment at the same concentration. In the early stage of DPCP-MT, the treatment interval was maintained. The treatment interval was gradually lengthened depending on the stability of the response and patient compliance. All patients were treated at the hospital until clinical improvement was achieved. After switching to DPCP-MT, 18 patients who maintained a complete response for [3 months were trained in appropriate home DPCP application and handling methods by a dermatologist. DPCP, Diphenylcyclopropenone.
remission. Furthermore, it emphasizes that treatment
Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis To the Editor: Alopecia areata (AA) is a T cellemediated autoimmune disease that causes nonscarring hair loss.
1 Some autoimmune diseases are associated with a vitamin D deficiency, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and vitiligo. 2, 3 Previous studies that evaluated vitamin D levels in patients with AA have reached inconsistent conclusions. This study aimed to perform a systematic review and metaanalysis on the association between vitamin D levels and AA.
This study covered all literature published before May 15, 2017. We included case-control studies in English that compared the prevalence of vitamin D deficiency or vitamin D levels in patients with AA and in controls. Review articles, case reports, and conference reports were excluded. Odds ratios were used to compare the prevalence of vitamin D deficiency in patients with AA and controls. Continuous data were analyzed using standardized mean difference, which accounted for the varied and related to maintenance treatment interval that affected relapse. Of the patients on diphenylcyclopropenone (DPCP) maintenance treatment (MT), we first compared the treatment interval of patients who a had relapse with those who did not. Because there was a significant difference in Interval mnt itself (P ¼ .022), we focused on the change in treatment interval before and after transition to DPCP-MT. The ratio of average treatment interval before and after transition to DPCP-MT, and the time until adjustment of DPCP-MT Interval mnt were also significantly different between the relapse and nonrelapse groups (P ¼ .021, P \ .01, respectively). AA, Alopecia areata; ANA, anti-nuclear antibody; CI, confidence interval; DPCP, diphenylcyclopropenone; conc, concentration. *Mean patient age was 40.4 years. y Extent of scalp hair loss: mild (0%-24%), moderate (25%-49%), severe (50%-74%), total (75%-100%). z ANA titers above 1:40 were classified as abnormal. 
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